%0 Journal Article %T Should we reconsider dual antiplatelet therapy duration following bioresorbable scaffold angioplasty? %A Buccheri, Dario %A Caramanno, Giuseppe %A Geraci, Salvatore %A Cortese, Bernardo %J Journal of Thoracic Disease %D 2017 %B 2017 %9 %! Should we reconsider dual antiplatelet therapy duration following bioresorbable scaffold angioplasty? %K %X In the last years, the fourth revolution of interventional cardiology, represented by bioresorbable vascular scaffolds (BVS), became real. BVS’s prerogatives are a good radial force to counter back acute vessel recoil for the time needed, then a complete disappearance after few years. Latest generation drug-eluting stents (DES) showed that a reduction in dual antiplatelet therapy (DAPT) could be afforded if clinically needed without incurring in thrombotic events (1,2), even if the DAPT trial showed that a 2.5 years prolonged DAPT was associated with reduced myocardial infarction, stent thrombosis (ST) and MACE, at the expense of higher bleeding rates (3- %U https://jtd.amegroups.org/article/view/12479 %V 9 %N 3 %P 417-418 %@ 2077-6624